upper
respiratori
tract
infect
urti
also
known
ent
infect
includ
rhiniti
nasopharyng
tonsil
otiti
media
om
compris
total
respiratori
aetiolog
urti
mostli
viral
primarili
caus
rhinoviru
hrv
parainfluenza
respiratori
syncyti
viru
rsv
influenza
adenoviru
coronaviru
upper
respiratori
tract
infect
common
autumnwint
europ
north
america
raini
season
tropic
children
prone
develop
rti
immun
system
yet
fulli
increas
exposur
viral
infect
day
care
attend
well
social
environment
factor
increas
risk
respiratori
system
primari
target
key
air
pollut
increas
risk
acut
recurr
pollut
disrupt
local
mucos
innat
immun
mechan
lead
bacteri
colonis
impair
kill
increas
allergen
permeabl
urti
associ
sequela
complic
includ
sever
lower
rti
lrti
develop
chronic
condit
need
surgeri
recurr
owe
high
morbid
mortal
healthcar
cost
effect
prevent
treatment
rti
high
prioriti
treatment
focus
symptom
relief
antihistamin
decongest
nasal
antituss
although
antibiot
indic
minor
patient
often
unnecessarili
prescrib
viral
infect
effect
recent
us
report
highlight
outpati
oral
antibiot
prescript
inappropri
antibiot
misus
led
emerg
resist
bacteria
mean
higher
dose
advanc
gener
drug
requir
present
infect
patient
treat
owe
current
unmet
need
effect
altern
conserv
therapi
effort
refocus
toward
prevent
strategi
behaviour
intervent
avoid
environment
risk
factor
passiv
highli
pollut
citi
area
vaccin
activ
target
immunis
target
medic
intervent
immunostimul
immunomodul
eg
bacteri
lysat
nutrit
includ
vitamin
eg
c
microel
regular
physic
activ
tabl
parent
children
recurr
rti
may
also
discuss
therapi
seen
advertis
herbal
eg
echinacea
homoeopath
remedi
product
eg
cod
liver
oil
thymu
extract
owe
signific
heterogen
lack
clinic
evid
support
mani
review
exist
therapi
avail
ent
infect
children
emphasi
immunomodul
administ
togeth
standard
care
immunomodulatori
strategi
treat
rti
enhanc
local
system
immun
respons
system
effect
relat
use
prepar
bacteri
lysat
bacteri
ribosom
display
effect
increas
system
polyclon
immunoglobulin
ig
synthesi
iga
igg
class
activ
sever
popul
immunocompet
cell
includ
lymphocyt
natur
killer
cell
b
lymphocyt
effect
consequ
report
vitro
vivo
experi
review
see
kearney
et
al
number
clinic
studi
shown
bacteri
lysat
bacteri
organel
eg
ribosom
appli
oral
effect
prevent
urti
lrti
children
decreas
number
durat
sever
infecti
episod
reduc
antibacteri
use
decreas
number
workschool
immunomodul
bacteri
lysat
particular
interest
sever
randomis
control
trial
summaris
systemat
review
demonstr
efficaci
children
plausibl
mechan
action
bacteri
lysat
propos
base
increas
immunoglobulin
respons
pathogen
mucos
surfac
also
activ
mucos
dendrit
cell
pattern
recognit
act
innat
adapt
immun
respons
recent
find
support
antivir
effect
eg
increas
interferon
ifn
interestingli
applic
bacteri
lysat
also
produc
system
effect
includ
increas
serum
immunoglobulin
system
cell
respons
bacteri
antigen
comprehens
review
mechan
action
bacteri
lysat
see
kearney
et
al
esposito
et
al
immunomodul
bacteri
lysat
empir
well
accept
use
medic
commun
decad
treat
one
commerci
avail
compound
incorpor
variou
clinic
treatment
guidelin
pan
american
associ
otorhinolaryngolog
head
neck
european
posit
epo
albeit
manag
specif
chronic
respiratori
condit
adult
studi
children
comprehens
evalu
highest
recommend
grade
recent
recommend
prevent
rti
children
sever
intern
system
strategi
includ
applic
medic
dietari
factor
may
enhanc
system
immun
respons
zinc
prepar
intak
vitamin
supplement
probiot
howev
clinic
effect
remain
debat
review
want
highlight
emerg
approach
conserv
manag
common
recurr
chronic
urti
children
emphasi
role
immunomodul
literatur
search
initi
conduct
march
updat
septemb
use
academ
search
complet
central
health
sourc
nursingacadem
edit
medlin
clinicaltrialsgov
cochran
databas
total
articl
retriev
review
two
independ
research
focus
primari
secondari
endpoint
report
systemat
review
randomis
control
trial
use
strategi
control
group
within
subpopul
larger
studi
exist
guidelin
intervent
observ
studi
novel
applic
also
includ
literatur
search
human
particip
involv
develop
review
ethic
committe
institut
review
board
approv
sought
obtain
necessari
obtain
inform
consent
patient
children
recurr
sever
croup
commonli
refer
paediatr
otolaryngologist
ent
specialist
assess
exclus
underli
anatom
congenit
upper
airway
disord
croup
occur
rate
second
year
life
peak
incid
month
year
around
annual
clinic
emerg
depart
visit
paediatr
rti
due
recurr
croup
children
typic
defin
three
croup
primarili
caus
parainfluenza
virus
well
rsv
virus
gener
spread
direct
inhal
cough
sneez
contamin
hand
follow
contact
fomit
subsequ
transfer
mucosa
eye
nose
mouth
treatment
croup
depend
sever
upper
airway
obstruct
risk
rapid
deterior
patient
condit
croup
typic
treat
agent
nebulis
oral
steroid
adrenalin
requir
urgent
case
sever
use
system
corticosteroid
earli
diseas
process
reduc
hospitalis
although
patient
still
requir
sever
treatment
guidelin
croup
current
avail
onlin
includ
howev
guidelin
provid
gener
measur
lower
risk
respiratori
infect
current
vaccin
target
virus
respons
croup
despit
number
attempt
develop
achiev
satisfactori
immunogen
prove
although
ongo
clinic
trial
see
clinicaltrialsgov
assess
new
vaccin
sinc
virus
also
caus
urti
could
therapeut
role
immunomodulatori
strategi
although
control
studi
requir
tonsil
common
among
children
usa
sore
throat
account
outpati
preval
bacteri
tonsil
among
affect
recurr
tonsil
children
defin
multipl
episod
acut
tonsil
burden
recurr
tonsil
substanti
may
lead
peritonsil
howev
overal
frequenc
magnitud
problem
recurr
tonsil
remain
unclear
treatment
tonsil
children
focus
reduc
symptom
avoid
complic
decreas
number
school
absenc
improv
qualiti
life
accord
clinic
practic
guidelin
treatment
bacteri
tonsil
antibiot
eg
penicillin
howev
european
countri
includ
germani
uk
netherland
recommend
antibiot
certain
wide
accept
indic
tonsillectomi
children
least
seven
clinic
signific
adequ
treat
sore
throat
defin
acut
pharyng
tonsil
acut
exud
tonsil
preced
year
least
five
episod
preced
year
least
three
episod
preced
surgeri
also
consid
episod
disabl
prevent
normal
function
prepar
seem
offer
attract
altern
approach
prevent
tonsil
firstli
retrospect
observ
studi
children
age
year
recurr
acut
tonsil
treat
commerci
avail
bacteri
lysat
decreas
frequenc
acut
tonsil
episod
month
figur
greater
decreas
number
episod
none
requir
tonsillectomi
subsequ
period
secondli
trial
oral
probiot
streptococcu
salivariu
children
complet
studi
signific
reduct
streptococc
pharyng
infect
episod
compar
previou
year
well
signific
decreas
incid
oral
viral
differ
observ
control
group
similar
result
observ
earlier
final
studi
children
age
year
pharyngotonsil
ribosom
immunotherapi
led
signific
improv
specif
immun
immun
may
therefor
effect
prophylaxi
recurr
acut
om
aom
viral
bacteri
infect
middl
ear
common
childhood
infect
antibiot
prescrib
recurr
aom
typic
defin
least
three
episod
period
four
episod
period
includ
least
one
episod
preced
number
risk
factor
aom
recurr
includ
winter
season
male
gender
passiv
approxim
children
age
less
year
treat
aom
experi
recurr
within
symptom
last
day
may
also
predict
treatment
approach
aom
depend
factor
patient
age
sever
sign
treatment
intervent
includ
treatment
watch
wait
predispos
condit
immunodefici
anatom
malform
cystic
fibrosi
ciliari
dyskinesia
need
exclud
greater
patientpar
educ
highlight
import
avoid
passiv
smoke
signific
factor
impair
mucos
immun
breastfeed
children
age
less
invas
intervent
insert
tympanostomi
tube
may
requir
children
recurr
aom
one
follow
age
less
year
underli
medic
condit
predispos
patient
recurr
comorbid
condit
associ
development
languag
delay
howev
gener
lack
consensu
regard
role
surgeri
parent
children
recurr
aom
usual
anxiou
pursu
surgic
treatment
option
often
seek
complementari
key
recommend
guidelin
american
academi
pediatr
aap
clinician
prescrib
prophylact
antibiot
reduc
frequenc
episod
aom
children
recurr
aom
pneumococc
influenza
vaccin
given
accord
schedul
recommend
aap
guidelin
inde
recent
analysi
found
epidemiolog
aom
chang
substanti
past
year
highlight
decreas
number
aom
episod
number
children
author
conclud
epidemiolog
shift
associ
introduct
pneumococc
conjug
vaccin
pcv
also
due
develop
stringent
diagnost
stop
smoke
ban
smoke
public
place
significantli
decreas
rate
children
emerg
depart
visit
middl
ear
infect
urti
accord
studi
massachusett
probiot
shown
ineffect
patient
may
role
use
vitamin
sinc
level
shown
significantli
lower
children
aom
compar
also
evid
incid
aom
children
reduc
use
microbi
prepar
exampl
frequenc
aom
assess
secondari
endpoint
two
clinic
studi
bacteri
lysat
involv
children
recurr
acut
rti
bacteri
lysat
treatment
reduc
total
number
om
episod
month
n
vs
respect
month
n
vs
respect
compar
placebo
note
randomis
control
italian
studi
prevent
urti
aom
studi
outcom
children
risk
factor
urti
histori
recurr
plan
eudract
ribosom
bacteri
immunotherapi
also
demonstr
efficaci
children
aom
studi
patient
age
year
ribosom
immunotherapi
led
significantli
improv
outcom
versu
placebo
incid
fever
well
frequenc
durat
infecti
ribosom
immunotherapi
led
signific
improv
clinic
score
immunolog
paramet
parent
assess
patient
symptom
hear
test
compar
placebo
studi
patient
age
addit
randomis
studi
includ
children
demonstr
significantli
lower
need
surgic
procedur
ribosom
immunotherapi
vs
placebo
patient
recurr
epo
group
defin
acut
rhinosinus
ar
sudden
onset
two
symptom
last
week
howev
older
classif
term
subacut
sinus
propos
repres
tempor
progress
symptom
week
contemporarili
defin
ar
although
chronic
rhinosinus
cr
defin
persist
sinu
inflamm
least
week
epo
group
feel
separ
term
describ
patient
prolong
ar
necessari
exacerb
cr
appropri
europ
children
urti
progress
mani
experi
recurr
point
preval
estim
cr
preval
vari
significantli
worldwid
partli
relat
differ
diagnost
criteria
use
eg
diagnosi
vs
inclus
object
rhinoscopi
imag
find
usa
preval
cr
rang
variou
eu
countri
averag
estim
south
america
caribbean
similar
differenti
recurr
ar
cr
difficult
reli
complet
resolut
symptom
patient
recurr
episod
ar
may
repres
distinct
clinic
patient
assess
underli
risk
factor
allergi
immunodefici
cystic
fibrosi
anatom
consider
imag
endoscop
evalu
nasalparanas
mucosa
first
interfac
inhal
toxin
pollut
environment
factor
thought
import
caus
transit
ar
cr
well
trigger
symptom
exacerb
exampl
signific
associ
passiv
smoke
care
analysi
underli
defect
perform
exampl
anatom
abnorm
prophylact
treatment
recurr
episod
almost
prevent
exacerb
cr
avoid
smoke
air
pollut
handwash
prevent
infect
howev
opinion
treatment
modal
cr
children
propos
pan
american
associ
epo
group
intern
consensu
statement
need
refin
sinc
import
studi
publish
recent
other
overlook
firstli
accord
recent
cochran
evalu
intranas
steroid
cr
children
effect
diseas
sever
although
symptomat
improv
nasal
blockag
rhinorrhoea
loss
sens
smell
facial
pain
base
observ
recommend
intranas
steroid
categori
iaa
option
children
recurr
ar
andor
secondli
randomis
studi
children
bacteri
lysat
recommend
iaa
option
epo
adult
cr
studi
children
comprehens
evalu
improv
cr
symptom
nasal
discharg
obstruct
reduc
frequenc
cr
exacerb
also
decreas
number
day
antibiot
usemonth
provid
moreov
studi
found
durat
acut
episod
shorter
bacteri
lysat
placebo
suggest
addit
valu
treatment
observ
support
two
randomis
studi
children
age
year
recurr
highlight
clinic
valu
immunomodulatori
approach
tabl
summaris
evid
recommend
manag
children
recurr
arsexacerb
cr
propos
epo
includ
recent
intern
consensu
statement
also
provid
recommend
treatment
immunis
lead
increas
host
resist
capabl
decreas
incid
acut
respiratori
vaccin
pneumococci
pneumococc
vaccin
result
signific
shift
caus
pathogen
acut
maxillari
sinus
children
frequenc
streptococcu
pneumonia
decreas
proport
haemophilu
influenza
increas
although
strong
evid
chang
incid
acut
bacteri
rhinosinus
widespread
use
pcv
h
influenza
type
b
vaccin
posit
anoth
group
agent
immunomodul
shown
reduc
number
season
decreas
frequenc
intens
ar
episod
cr
base
evid
adult
cr
without
nasal
epo
paper
pan
american
associ
otorhinolaryngolog
head
neck
surgeri
guidelin
recommend
bacteri
lysat
although
nevertheless
substanti
evid
support
valu
bacteri
lysat
reduc
risk
acut
rti
children
evidenc
cochran
recent
larg
almost
paediatr
clinic
studi
highlight
prevent
exacerb
cr
recurr
support
find
sever
consensu
paper
guidelin
note
could
play
role
prevent
recurr
rhinosinus
season
urti
common
caus
recurr
arsexacerb
cr
cochran
review
evalu
zinc
common
cold
includ
randomis
control
trial
children
adult
conclud
zinc
could
shorten
episod
durat
children
also
use
prevent
research
focu
effect
zinc
patient
greater
risk
develop
complic
common
cold
recent
randomis
control
trial
includ
children
adult
found
vitamin
supplement
significantli
reduc
risk
acut
rti
avail
evid
assess
high
although
larg
number
randomis
control
trial
perform
assess
echinacea
common
weak
trial
method
differ
intervent
make
difficult
draw
conclus
effect
children
similarli
despit
larg
number
studi
wide
varieti
avail
data
accord
systemat
review
evid
support
use
vitamin
c
supplement
common
cold
although
antimicrobi
retain
import
role
medicin
use
becom
less
accept
modern
societi
particularli
certain
condit
administ
prevent
measur
rapid
emerg
resist
bacteria
jeopardis
efficaci
antibiot
inde
decreas
use
antibiot
consid
top
prioriti
healthcar
author
around
world
avoid
consequ
effect
overus
increas
antibiot
resist
mucosa
microbiom
new
treatment
prevent
modal
respiratori
infect
expect
welcom
modul
human
immun
system
becom
increasingli
relev
gener
infecti
diseas
allergi
gastroenterolog
also
disciplin
oncolog
disord
review
discuss
clinic
evid
support
use
select
immunomodulatori
strategi
children
specif
ent
condit
howev
remain
barrier
widespread
use
therapi
exampl
avail
data
specif
ent
infect
remain
spars
although
evid
around
prevent
gener
rti
robust
ideal
new
studi
perform
specif
ent
infect
children
order
increas
evid
base
support
treatment
recommend
addit
accord
avail
mani
commerci
avail
product
demonstr
moder
effect
import
gener
research
data
use
immunomodulatori
strategi
patient
specif
urti
upper
respiratori
tract
diseas
wf
speaker
sandoz
vifor
pharma
pierr
fabr
gsk
rm
asv
kr
declar
conflict
interest
jlmb
speaker
msd
carnot
particip
advisor
msd
vifor
pharma
